Senshio (Ospemifene) 60 mg
Oral selective estrogen receptor modulator (SERM) for moderate to severe postmenopausal vulvovaginal atrophy
Quick facts about Senshio
Key takeaways about Senshio
- Targeted oral therapy for vaginal atrophy: Senshio is the first oral non-hormonal treatment approved in Europe for moderate to severe postmenopausal vulvar and vaginal atrophy (VVA)
- Tissue-selective action: Ospemifene acts as an estrogen agonist on the vaginal epithelium but is neutral or antagonist in breast and endometrial tissue, offering a different safety profile than systemic estrogen
- Simple once-daily dosing: One 60 mg tablet is taken orally with food every day at the same time — a convenient alternative to local vaginal products
- Not for everyone: Senshio must not be used in women with active or past blood clots, estrogen-dependent cancer, undiagnosed vaginal bleeding, severe liver disease, or endometrial hyperplasia
- Full benefit at 12 weeks: Most women experience significant improvement in dyspareunia and vaginal dryness by week 12, though some notice changes earlier
What Is Senshio and What Is It Used For?
Senshio (ospemifene) is an oral selective estrogen receptor modulator (SERM) used to treat moderate to severe symptoms of vulvar and vaginal atrophy (VVA) in postmenopausal women who are not suitable candidates for local vaginal estrogen therapy. It relieves vaginal dryness, burning, irritation, and painful sexual intercourse (dyspareunia).
Senshio contains the active substance ospemifene, a non-steroidal molecule belonging to a class of medicines called selective estrogen receptor modulators (SERMs). Unlike traditional estrogen replacement therapy, ospemifene has tissue-selective activity: it behaves like estrogen in some parts of the body (the vaginal lining and bones) while exerting neutral or anti-estrogenic effects in others (breast and uterine tissue). This selectivity gives it a distinct risk–benefit profile from systemic hormone therapy.
Senshio is indicated for adult postmenopausal women who experience moderate to severe symptoms of vulvar and vaginal atrophy — a chronic, progressive condition caused by the drop in circulating estrogens that follows natural or surgical menopause. Vulvovaginal atrophy (also called genitourinary syndrome of menopause, GSM) affects an estimated 50–70% of postmenopausal women, yet is widely under-diagnosed and under-treated. Senshio was specifically approved for women in whom local vaginal estrogen therapy (creams, tablets, or rings) is not appropriate, not well tolerated, or who prefer an oral, non-hormonal alternative.
Understanding Postmenopausal Vulvovaginal Atrophy
Before menopause, estrogen maintains the thickness, elasticity, and moisture of the vaginal lining and keeps the vaginal pH acidic through the activity of lactobacilli. After the menopausal transition — typically occurring between the ages of 45 and 55 — circulating estradiol levels fall sharply. The consequences include thinning (atrophy) of the vaginal and vulvar epithelium, loss of elasticity, reduced lubrication, a shift in vaginal pH toward more alkaline values, and increased susceptibility to irritation and infections.
Typical symptoms include vaginal dryness, burning or itching, irritation, painful intercourse (dyspareunia), light bleeding during or after sex, and sometimes urinary symptoms such as frequency, urgency, or recurrent urinary tract infections. Unlike hot flushes, these symptoms rarely improve without treatment — in fact, they tend to become more severe over time. Vulvovaginal atrophy can significantly impair quality of life, sexual function, and intimate relationships.
How Does Senshio Work?
Ospemifene binds to both estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), the same nuclear receptors activated by endogenous estrogens. What makes it a selective modulator is the way the receptor conformation differs when bound to ospemifene compared with estradiol: this causes the receptor to recruit different co-activator and co-repressor proteins depending on the tissue, producing estrogen-like effects in some tissues and anti-estrogenic effects in others.
In the vaginal epithelium, ospemifene acts as a potent estrogen agonist. Clinical studies using vaginal cytology show that treatment with Senshio increases the proportion of mature superficial cells and decreases the proportion of parabasal cells, indicating restoration of normal epithelial thickness. Vaginal pH also decreases (becoming more acidic) toward premenopausal values, a marker of restored lactobacillus activity and healthier vaginal flora.
In contrast, in breast tissue, ospemifene behaves as an antagonist or weak partial agonist in preclinical models, and clinical data have not shown an increased risk of breast proliferation during the studied treatment period. In the endometrium, its action is weak; small increases in endometrial thickness may occur but without evidence of hyperplasia or cancer in the pivotal trials. It also has mild estrogen-agonist effects on bone turnover markers, similar in direction but smaller in magnitude than raloxifene.
In two pivotal 12-week phase III trials (studies 15-50310 and 15-50821) and long-term extension studies, Senshio 60 mg daily significantly improved vaginal maturation index, reduced vaginal pH, relieved severe dyspareunia, and decreased severe vaginal dryness compared with placebo. Benefits were generally sustained throughout 52 weeks of continuous therapy.
Because ospemifene's action depends on binding estrogen receptors, it must not be used in women with estrogen-dependent cancers such as breast cancer. It is also not appropriate for women who have not yet completed menopause, since in women still producing endogenous estrogens, adding a SERM could interfere with ovarian function and bone metabolism in unpredictable ways.
What Should You Know Before Taking Senshio?
Before starting Senshio, tell your doctor about any history of blood clots, breast or other hormone-sensitive cancer, liver disease, undiagnosed vaginal bleeding, or use of estrogens or other SERMs. Senshio is for postmenopausal women only and is not to be used during pregnancy or breastfeeding.
Senshio is a powerful medicine that interacts with estrogen receptors throughout the body. Certain medical conditions and circumstances mean that it is either completely unsuitable or should be used only under careful medical supervision. Always provide your doctor with a full medical history, including past and current diagnoses, previous surgeries, and all medications, supplements, and herbal products you are taking.
Contraindications
You must not take Senshio if any of the following applies to you:
- Hypersensitivity to ospemifene or any of the excipients in the tablet.
- You are pre-menopausal (not yet in menopause) or are a woman of child-bearing potential.
- You are pregnant or breastfeeding, or think you may be pregnant.
- You have a history of venous thromboembolism (VTE) — including deep vein thrombosis (DVT), pulmonary embolism, or retinal vein thrombosis — or currently have one.
- You have a history of, or currently have, an arterial thromboembolic disease such as a heart attack (myocardial infarction), stroke, or transient ischaemic attack (TIA).
- You have undiagnosed vaginal bleeding.
- You have or have had breast cancer (known, suspected, or history of).
- You have or are suspected of having an estrogen-dependent malignancy (for example, endometrial cancer).
- You have endometrial hyperplasia (abnormal thickening of the lining of the womb) that has not been treated.
- You have severe hepatic impairment (severe liver disease).
Warnings and Precautions
Senshio is not suitable for every postmenopausal woman. Your doctor will carry out a thorough personal and family medical evaluation before starting treatment and will repeat this assessment periodically during therapy. Particular attention must be paid to the following:
Endometrial safety
Although ospemifene has only a weak estrogen-agonist effect on the endometrium, small increases in endometrial thickness have been observed in some women treated with Senshio. You should report any unusual vaginal bleeding, spotting, or brown discharge to your doctor promptly. In postmenopausal women, unscheduled bleeding always requires investigation to exclude endometrial hyperplasia or cancer. Women with a history of endometrial hyperplasia should not take Senshio unless the hyperplasia has been fully treated.
Venous thromboembolism (VTE) risk
As with estrogen therapy and other SERMs, ospemifene is associated with a small increased risk of venous thromboembolism. Risk factors that may further increase your chance of developing a blood clot include personal or family history of VTE, obesity (body mass index above 30 kg/m²), smoking, prolonged immobilisation (for example, after major surgery or long-haul travel), certain inherited blood-clotting disorders, and cancer. Your doctor will weigh these factors before prescribing Senshio and may recommend temporarily stopping treatment before planned surgery or extended bed rest.
Breast cancer history or risk
Senshio has not been studied in women with a history of breast cancer. It must not be used in women who have had breast cancer or are being treated for it. Before starting therapy, inform your doctor about any family history of breast cancer, any personal history of abnormal mammograms or breast biopsies, and ensure that your breast-screening programme (mammography) is up to date.
Ovarian and uterine abnormalities
Women with pre-existing uterine fibroids, adenomyosis, or any other estrogen-sensitive condition should discuss the suitability of Senshio with their gynaecologist.
Liver function
Ospemifene is extensively metabolised in the liver. It must not be used in women with severe liver impairment. In moderate hepatic impairment, pharmacokinetic data are limited, so treatment should be avoided unless the benefits clearly outweigh the risks. Routine liver function testing is not required for healthy women, but your doctor may request tests if you develop symptoms of liver problems (unusual fatigue, yellowing of the skin or eyes, right upper-abdominal pain, dark urine).
Stop Senshio and contact your doctor or emergency services immediately if you develop any of the following: swelling or pain in a leg (possible DVT), sudden chest pain or breathlessness (possible pulmonary embolism), sudden severe headache, visual disturbance or weakness on one side of the body (possible stroke), or unexplained vaginal bleeding between expected (or long-absent) periods. These may be signs of a serious complication that requires urgent assessment.
Pregnancy, Breastfeeding and Fertility
Senshio is intended exclusively for postmenopausal women and is contraindicated in pregnancy and breastfeeding. Animal studies have shown reproductive toxicity, and there are no data on the use of ospemifene in pregnant women. If you have only recently entered the menopause and pregnancy cannot be absolutely excluded, a pregnancy test must be performed before starting therapy. If you become pregnant during treatment, stop Senshio immediately and contact your doctor.
It is not known whether ospemifene is excreted in human milk. Because breastfeeding implies that the woman has not yet reached menopause, breastfeeding women should not use Senshio.
Children and Adolescents
Senshio is not indicated for use in children or adolescents. There is no relevant use of Senshio in the paediatric population, and safety and efficacy have not been established in individuals under 18 years of age.
Driving and Using Machines
Senshio has no or negligible influence on the ability to drive and use machines. However, some women have reported dizziness or fatigue when starting therapy. If you experience these symptoms, wait until they resolve before driving or operating heavy machinery.
Excipients of Note
Senshio tablets contain lactose monohydrate. Women with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine. Each tablet contains less than 1 mmol of sodium (23 mg), meaning it is essentially “sodium-free”.
How Does Senshio Interact with Other Drugs?
Senshio is metabolised primarily by CYP3A4 and CYP2C9 enzymes, so strong inhibitors or inducers can significantly alter its blood levels. Fluconazole, rifampicin, warfarin, and systemic estrogens are the most clinically important interactions. Always tell your healthcare team about every medicine and supplement you take.
Drug interactions with ospemifene occur mainly through two mechanisms: (1) alterations in ospemifene metabolism through the hepatic cytochrome P450 enzymes CYP3A4 and CYP2C9, and (2) effects on highly protein-bound drugs such as warfarin, because ospemifene itself is more than 99% protein-bound. Understanding these interactions helps your doctor and pharmacist anticipate problems and adjust doses or monitoring as needed.
Major Interactions
| Interacting Drug/Class | Interaction Mechanism | Clinical Significance | Recommendation |
|---|---|---|---|
| Fluconazole (antifungal) | Strong CYP2C9 and moderate CYP3A4 inhibition → 2.7-fold increase in ospemifene AUC | Major | Not recommended concomitantly |
| Rifampicin (antibiotic/antituberculous) | Strong CYP3A4 inducer → significantly reduced ospemifene levels | Major | Avoid combination; efficacy may be lost |
| Systemic estrogens (oral or transdermal HRT) | Overlapping action on estrogen receptors; unknown effect on uterus and breast | Major | Concomitant use not recommended |
| Other SERMs (tamoxifen, raloxifene, toremifene) | Competitive action on estrogen receptors; additive unknown effects | Major | Not recommended |
| Ketoconazole, itraconazole (strong CYP3A4 inhibitors) | Increased plasma concentration of ospemifene | Major | Caution; avoid or reduce exposure if possible |
Moderate and Minor Interactions
| Interacting Drug/Class | Interaction Mechanism | Clinical Significance | Recommendation |
|---|---|---|---|
| Warfarin and other coumarin anticoagulants | Protein-binding displacement and possible CYP2C9 effects | Moderate | Monitor INR more frequently after initiation or dose change |
| Phenytoin, carbamazepine, phenobarbital | Moderate to strong CYP3A4 induction | Moderate | Ospemifene efficacy may be reduced; consider alternatives |
| St John's wort (Hypericum perforatum) | CYP3A4 induction | Moderate | Avoid concomitant use |
| Grapefruit juice | CYP3A4 inhibition in the gut | Minor–Moderate | Avoid large or regular quantities |
| Sulfonylureas (e.g. glimepiride) and NSAIDs | Highly protein-bound drugs; potential displacement | Minor | Clinical significance low; standard monitoring suffices |
Because of the protein-binding profile, ospemifene theoretically can displace other highly protein-bound drugs, but the clinical significance of this has been shown to be low for most medications. The exception is warfarin, where slightly more frequent INR monitoring is advisable when starting or stopping Senshio.
Tell your doctor and pharmacist about all the medicines you are taking, including prescription drugs, over-the-counter medicines, vitamins, herbal products, and supplements. This is particularly important for women taking anticoagulants, anti-seizure drugs, antibiotics, antifungals, or any hormonal therapy.
Senshio should not be combined with systemic estrogen replacement therapy (HRT) or other SERMs such as tamoxifen or raloxifene. Combining these medicines has not been studied and could expose the endometrium and breast to unpredictable estrogen-receptor activity.
What Is the Correct Dosage of Senshio?
The recommended dose of Senshio is one 60 mg film-coated tablet taken once daily with food. Take it at the same time every day. The need for continued treatment should be reviewed at regular intervals by your prescribing doctor.
Senshio is supplied as 60 mg film-coated tablets and is taken by mouth. The dose is one tablet per day, and there is no tapering or titration — the 60 mg dose is the only strength available because it is the dose used in the pivotal phase III studies. Taking the tablet with food is important because it increases bioavailability approximately twofold and provides more predictable plasma levels.
Adults (Postmenopausal Women)
Standard dose
Dose: 60 mg once daily
Route: Oral
Administration: Swallow whole with a glass of water, taken with food (for example, with breakfast or dinner). Take at approximately the same time each day.
Duration: Treatment should continue only as long as the benefits outweigh the risks. Re-evaluate with your prescribing doctor at least once a year.
Elderly Patients (65 Years and Older)
No dose adjustment required
No dose adjustment is necessary for postmenopausal women aged 65 years and older. Pharmacokinetic studies have shown similar ospemifene exposure in women aged 75+ compared with women aged 50–65. However, older women should be monitored carefully for thromboembolic complications and any unusual vaginal bleeding, because the absolute risk of these events increases with age.
Renal Impairment
Mild to severe renal impairment
No dose adjustment is required in women with mild, moderate, or severe renal impairment, as ospemifene is predominantly eliminated by hepatic metabolism rather than the kidneys. Fewer than 1% of an oral dose is excreted unchanged in urine.
Hepatic Impairment
Caution required
No dose adjustment is required in mild hepatic impairment (Child-Pugh A). In moderate hepatic impairment (Child-Pugh B), pharmacokinetic data are limited and Senshio should be used with caution. In severe hepatic impairment (Child-Pugh C), Senshio is contraindicated and must not be used.
Children and Adolescents
Senshio is not approved for use in patients under 18 years of age. There is no relevant use of ospemifene in the paediatric population because the indication — postmenopausal vulvovaginal atrophy — does not apply to children or adolescents.
How to Take the Tablets Step by Step
Follow these steps to maximise the benefit of your medicine and minimise any side effects:
- Choose a regular time each day that you associate with a meal — for example, with breakfast or with your evening meal. Taking Senshio with food increases absorption and provides more consistent blood levels.
- Take one tablet with a glass of water. Swallow it whole — do not crush, split, or chew the tablet, as this may affect the release and absorption.
- Do not double-dose. If you accidentally take more than one tablet, contact your doctor or a poison control centre.
- Keep the tablets in the original blister until you are ready to take them. The blister protects the tablets from moisture and light.
- Continue daily until your doctor tells you to stop. Stopping treatment means the vaginal tissues will gradually return to the atrophic, pre-treatment state.
Missed Dose
If you forget to take a dose, take it as soon as you remember on the same day, unless it is almost time for your next dose. If you are close to the time for your next scheduled dose, simply skip the missed dose and continue with your regular schedule. Do not take a double dose to make up for a missed one.
Overdose
There is no specific experience with ospemifene overdose in humans. Doses up to 200 mg/day (more than three times the recommended dose) have been studied in healthy volunteers for short periods without serious safety concerns. If you suspect you have taken more Senshio than prescribed, contact your doctor, pharmacist, or the nearest hospital emergency department. Bring the medicine pack with you. There is no specific antidote; management would be symptomatic and supportive, as ospemifene is highly protein-bound and is unlikely to be removed effectively by dialysis.
Guidelines recommend that any estrogen-related therapy, including Senshio, be re-evaluated at least once a year. At these reviews, your doctor will reassess your symptoms, update your medical history, review any changes in risk factors (for example, new diagnoses of hypertension, diabetes, or thromboembolism), check for any abnormal bleeding, and confirm that mammography and gynaecological screening are up to date.
What Are the Side Effects of Senshio?
The most common side effects of Senshio are hot flushes (very common, affecting more than 1 in 10 women), followed by muscle spasms, vaginal discharge, genital discharge, headache, and rash (common). Uncommon side effects include allergic reactions and venous thromboembolism. Most side effects are mild to moderate and tend to settle over the first weeks of therapy.
Like all medicines, Senshio can cause side effects, although not everybody gets them. The following frequency categories are based on data from controlled clinical trials and post-marketing surveillance, and align with the convention used by the European Medicines Agency. Understanding what is expected and what is unusual helps you recognise when to simply continue therapy and when to contact your doctor.
Very Common
- Hot flushes (flushing, sudden waves of warmth and sweating)
Common
- Vulvovaginal candidiasis (genital thrush / yeast infection)
- Genital or vaginal discharge
- Muscle spasms, particularly leg cramps
- Headache
- Rash
- Increased blood pressure
- Excessive sweating (hyperhidrosis)
Uncommon
- Hypersensitivity reactions (allergic skin reactions)
- Endometrial thickening
- Uterine polyps
Rare
- Venous thromboembolism (deep vein thrombosis, pulmonary embolism)
- Retinal vein thrombosis
Not Known
- Angioedema (swelling of the face, lips or tongue)
Understanding the Most Common Side Effects
Hot flushes are the most frequently reported side effect and reflect ospemifene's partial anti-estrogenic activity in thermoregulatory centres. They are usually mild to moderate, similar in character to the vasomotor symptoms many women experience around menopause, and tend to lessen after the first few weeks of therapy. Practical measures such as wearing layered clothing, keeping rooms cool, avoiding trigger foods (hot drinks, spicy food, alcohol), and reducing stress can help. If hot flushes are severe and persistent, discuss them with your doctor.
Muscle spasms, especially nocturnal leg cramps, are another class effect of SERMs. Adequate hydration, gentle stretching before bed, and ensuring sufficient intake of potassium, magnesium and calcium through diet may help. Contact your doctor if cramps are severe, frequent, or accompanied by leg pain, swelling or redness, which could indicate a blood clot.
Vaginal or genital discharge is expected as the vaginal epithelium becomes thicker and secretes more fluid in response to improved estrogenic signalling. Discharge that is white or clear and non-irritating is generally a normal part of treatment response. However, discharge that is yellow, green, blood-tinged, foul-smelling, or accompanied by itching, burning, or fever may indicate infection and should be evaluated.
Understanding the Serious but Rare Side Effects
The most important serious side effect associated with SERMs is venous thromboembolism (VTE). This includes deep vein thrombosis (usually in the legs), pulmonary embolism (clot that has travelled to the lung), and rarely retinal vein thrombosis (clot in the eye). VTE is rare (less than 1 in 1,000), but risk may be higher in women with obesity, smoking, recent surgery, prolonged bed rest, or an inherited clotting disorder. Watch for sudden leg pain and swelling, chest pain, breathlessness, or visual changes — and seek urgent medical attention if they occur.
Endometrial thickening and polyps have been observed in some women taking Senshio. These are usually found only during gynaecological examination. The clinical significance is generally low, but any unscheduled bleeding in a postmenopausal woman warrants investigation, which may include transvaginal ultrasound, endometrial biopsy, or hysteroscopy.
Seek immediate medical attention if you experience: sudden chest pain, difficulty breathing, or coughing up blood (possible pulmonary embolism); severe pain or swelling in one leg (possible DVT); sudden loss of vision, partial loss of vision, or blurred vision (possible retinal thrombosis); sudden severe headache with weakness on one side of the body or slurred speech (possible stroke); or swelling of the face, lips, tongue or throat with difficulty breathing (possible angioedema or anaphylaxis).
Reporting Side Effects
Reporting suspected side effects after a medicine has been authorised is essential. It allows continued monitoring of the benefit–risk balance. If you experience any side effects, talk to your doctor, pharmacist, or nurse. You can also report side effects directly via your national pharmacovigilance system, such as the MHRA Yellow Card Scheme (United Kingdom), the FDA MedWatch programme (United States), or the EMA EudraVigilance system (European Union). Your reports help improve the safety profile of medicines for everyone.
How Should You Store Senshio?
Store Senshio in its original blister packaging below 30°C. Keep the medicine out of the sight and reach of children. Do not use after the expiry date printed on the pack. Return any unused or expired tablets to a pharmacy for safe disposal — never throw medicines in household waste or down the drain.
Correct storage is important to ensure that Senshio retains its full potency and safety until you use it. Because the tablets are film-coated and sealed in a blister, they are well-protected from moisture, but ordinary household storage conditions should still be respected. Follow these rules:
- Keep below 30°C (86°F). Avoid hot places such as window sills, the top of kitchen appliances, or a car glove compartment.
- Keep in the original packaging until each tablet is ready to be taken. The blister provides physical protection and the carton protects against light.
- Do not refrigerate or freeze. Refrigeration is not necessary and not recommended.
- Check the expiry date (EXP) printed on the carton and blister. Do not use after this date; the expiry date refers to the last day of that month.
- Keep out of the sight and reach of children. Even a small number of tablets may be harmful if swallowed by a child.
- Do not use if the blister is damaged, or if a tablet appears broken, chipped, or discoloured.
Do not dispose of medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment from pharmaceutical contamination.
What Does Senshio Contain?
Each Senshio film-coated tablet contains 60 mg of ospemifene as the active substance. The tablet also contains several inactive ingredients (excipients) used to stabilise and coat the formulation, including lactose monohydrate, mannitol, microcrystalline cellulose, and titanium dioxide in the film coat.
Active Ingredient
The active substance is ospemifene. Each film-coated tablet contains 60 mg of ospemifene. Ospemifene is a non-steroidal small molecule chemically related to other triphenylethylene SERMs such as tamoxifen and toremifene, but with a different pharmacological profile that favours estrogen-agonist activity on the vaginal epithelium.
Inactive Ingredients (Excipients)
The other ingredients are:
Tablet core:
- Mannitol (E 421)
- Microcrystalline cellulose (E 460)
- Sodium starch glycolate (type A)
- Colloidal anhydrous silica
- Magnesium stearate (E 470b)
- Lactose monohydrate
- Hypromellose (E 464)
Film-coating:
- Polyvinyl alcohol (E 1203)
- Titanium dioxide (E 171)
- Macrogol 3350
- Talc (E 553b)
Please note: Senshio contains lactose monohydrate. Women with rare hereditary galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine. The tablet also contains less than 1 mmol of sodium per tablet, meaning it is essentially “sodium-free”.
Appearance and Pack Sizes
Senshio tablets are oval, biconvex, white to off-white, film-coated tablets, debossed with the marking “60” on one side. They are supplied in blister packs within an outer carton. Pack sizes include:
- 28 film-coated tablets (4-week supply)
- 84 film-coated tablets (3-month supply)
Not all pack sizes may be marketed in all countries. The marketing authorisation holder in the European Union is Shionogi B.V., Amsterdam, the Netherlands. In the United States, the brand Osphena is marketed by Duchesnay USA. Ospemifene was originally developed by Hormos Medical/QuatRx Pharmaceuticals and is licensed in various regions under different brand names.
Frequently Asked Questions About Senshio
Senshio (ospemifene) 60 mg film-coated tablets are used to treat moderate to severe symptoms of vulvar and vaginal atrophy (VVA) in postmenopausal women who are not suitable candidates for local vaginal estrogen therapy. VVA — also known as genitourinary syndrome of menopause (GSM) — is a chronic condition caused by the drop in estrogen after menopause, leading to vaginal dryness, burning, irritation, and painful intercourse (dyspareunia). Senshio helps restore the vaginal tissue and relieves these symptoms.
Senshio is not a hormone but a selective estrogen receptor modulator (SERM). Traditional hormone replacement therapy (HRT) contains estrogens (sometimes with a progestogen) and acts like estrogen in most tissues of the body, including breast and uterus. Senshio, by contrast, acts like estrogen mainly on the vaginal epithelium while having neutral or anti-estrogenic effects on breast and endometrial tissue. This selectivity means it targets vaginal symptoms without the full systemic estrogenic profile of HRT. It is taken orally as a daily tablet rather than as a vaginal cream, tablet or ring.
Some women notice an improvement in vaginal dryness and painful intercourse within the first 4 weeks of daily treatment, but the full benefit is typically seen after 12 weeks. In the pivotal clinical trials, statistically significant improvements in vaginal cell maturation, vaginal pH, and dyspareunia severity were demonstrated at 12 weeks compared with placebo. Continue taking Senshio every day even if you do not notice immediate improvement, and discuss progress with your doctor at your next review.
No. Senshio must not be used in women who have or have had breast cancer, or in whom breast cancer is suspected. Senshio has not been studied in this population, and the long-term effects on breast tissue are not fully characterised in women with a history of breast cancer. If you are taking tamoxifen or an aromatase inhibitor for breast cancer, these also should not be combined with Senshio. If you have symptoms of vulvovaginal atrophy and a history of breast cancer, discuss non-hormonal options (moisturisers, lubricants, vaginal laser therapy) with your oncologist and gynaecologist.
Yes. Senshio should be taken with food. Taking ospemifene with a meal increases its absorption approximately twofold compared with fasting and provides more predictable plasma levels. Choose a consistent time of day that coincides with a regular meal, such as breakfast or dinner. Swallow the tablet whole with water; do not crush, split, or chew the tablet.
If you miss a dose, take it as soon as you remember on the same day. If it is almost time for your next dose, skip the missed dose and continue with your usual schedule. Do not take a double dose to make up for a missed tablet. If you have missed several doses in a row, contact your doctor or pharmacist for advice.
Like other SERMs and estrogen therapies, ospemifene is associated with a small increased risk of venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism. The absolute risk is low (rare, less than 1 in 1,000), but may be higher in women with pre-existing risk factors such as obesity, smoking, prior VTE, recent surgery, or prolonged immobilisation. Senshio is contraindicated in women with a current or past history of VTE or arterial thromboembolic disease. Stop the medicine and seek urgent medical attention if you develop leg pain and swelling, chest pain, or sudden breathlessness.
Senshio can be continued for as long as the benefits (symptom relief) outweigh the risks. Most regulatory guidance recommends reviewing the need for continued treatment at least once a year. In clinical trials, safety has been documented for up to 52 weeks of continuous use. If symptoms recur after stopping treatment, your doctor may consider restarting Senshio after re-evaluating contraindications and risk factors.
References
This article is based on the following peer-reviewed sources and regulatory documents:
- European Medicines Agency (EMA). Senshio (ospemifene) — Summary of Product Characteristics and European Public Assessment Report. Available at: EMA EPAR: Senshio.
- U.S. Food and Drug Administration (FDA). Osphena (ospemifene) Prescribing Information. Revised 2024.
- Portman DJ, Bachmann GA, Simon JA; Ospemifene Study Group. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause. 2013;20(6):623-630. doi:10.1097/GME.0b013e318279ba64.
- Bachmann GA, Komi JO; Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause. 2010;17(3):480-486.
- Goldstein SR, Bachmann GA, Koninckx PR, et al. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric. 2014;17(2):173-182.
- The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-992.
- Panay N, Ang SB, Cheshire R, Goldstein SR, Maki P, Nappi RE; International Menopause Society Board. Menopause and MHT in 2024: addressing the key controversies — an International Menopause Society White Paper. Climacteric. 2024;27(5):441-457.
- World Health Organization (WHO). International Classification of Diseases, 11th Revision (ICD-11) — Genitourinary syndrome of menopause. Geneva: WHO; 2024.
- British National Formulary (BNF). Ospemifene. National Institute for Health and Care Excellence (NICE). Accessed December 2025.
- Cui Y, Zong H, Yan H, Li N, Zhang Y. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvovaginal atrophy: a systematic review and meta-analysis. J Sex Med. 2014;11(2):487-497.
About Our Medical Editorial Team
All medical content on iMedic is written and reviewed by a team of qualified healthcare professionals with expertise in their respective fields. Our editorial process follows international medical guidelines and the GRADE evidence framework.
Content written by medical professionals with clinical experience in gynaecology, menopause medicine, and women's health. All claims are referenced to peer-reviewed literature.
Independently reviewed by the iMedic Medical Review Board. Content follows EMA, FDA, and IMS/NAMS international guidelines for accuracy and clinical relevance.
Evidence Level 1A — based on systematic reviews and randomised controlled trials. Following the GRADE framework for evidence quality assessment.
No pharmaceutical company sponsorship. No commercial funding. All content is independently produced with no conflicts of interest.